Cedric Francois Sells 19,725 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) CEO Cedric Francois sold 19,725 shares of the stock in a transaction on Thursday, July 17th. The stock was sold at an average price of $20.21, for a total value of $398,642.25. Following the transaction, the chief executive officer owned 331,605 shares in the company, valued at $6,701,737.05. The trade was a 5.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Cedric Francois also recently made the following trade(s):

• On Tuesday, July 15th, Cedric Francois sold 1,900 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $20.09, for a total value of $38,171.00.
• On Monday, July 14th, Cedric Francois sold 137,465 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $20.19, for a total value of $2,775,418.35.

Apellis Pharmaceuticals Price Performance

Apellis Pharmaceuticals stock traded down $0.57 during midday trading on Friday, reaching $19.47. The company's stock had a trading volume of 1,842,831 shares, compared to its average volume of 2,366,386. Apellis Pharmaceuticals, Inc. has a 52 week low of $16.10 and a 52 week high of $41.94. The company has a current ratio of 4.08, a quick ratio of 3.62 and a debt-to-equity ratio of 2.76. The business has a 50-day moving average price of $18.19 and a 200-day moving average price of $22.73. The stock has a market cap of $2.45 billion, a PE ratio of -10.88 and a beta of 0.67.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 28.83% and a negative return on equity of 99.19%. The business had revenue of $149.90 million during the quarter, compared to the consensus estimate of $197.61 million. During the same quarter in the prior year, the firm earned ($0.54) EPS. The business's revenue was down 3.2% on a year-over-year basis. On average, sell-side analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. EverSource Wealth Advisors LLC grew its position in Apellis Pharmaceuticals by 2,707.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock valued at $25,000 after acquiring an additional 758 shares during the last quarter. Signaturefd LLC grew its position in Apellis Pharmaceuticals by 357.2% in the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company's stock valued at $37,000 after acquiring an additional 918 shares during the last quarter. Assetmark Inc. boosted its stake in shares of Apellis Pharmaceuticals by 3,938.7% during the first quarter. Assetmark Inc. now owns 1,252 shares of the company's stock valued at $27,000 after purchasing an additional 1,221 shares in the last quarter. Parallel Advisors LLC boosted its stake in shares of Apellis Pharmaceuticals by 80.0% during the second quarter. Parallel Advisors LLC now owns 1,924 shares of the company's stock valued at $33,000 after purchasing an additional 855 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of Apellis Pharmaceuticals during the fourth quarter valued at about $83,000. Institutional investors own 96.29% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on APLS shares. Raymond James Financial cut Apellis Pharmaceuticals from a "strong-buy" rating to an "outperform" rating and lowered their price objective for the stock from $75.00 to $52.00 in a research report on Friday, May 9th. Royal Bank Of Canada lowered their price objective on Apellis Pharmaceuticals from $21.00 to $18.00 and set a "sector perform" rating on the stock in a research report on Thursday, May 8th. Morgan Stanley increased their price objective on Apellis Pharmaceuticals from $25.00 to $26.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 2nd. Wells Fargo & Company increased their price objective on Apellis Pharmaceuticals from $26.00 to $29.00 and gave the stock an "equal weight" rating in a research report on Monday, June 2nd. Finally, Mizuho lowered their price objective on Apellis Pharmaceuticals from $30.00 to $20.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 14th. Nine research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Apellis Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $40.00.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.